Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

The ReliantHeart aVAD© 

The ReliantHeart aVAD©
Chapter:
The ReliantHeart aVAD©
Author(s):

Bryan E. Lynch

DOI:
10.1093/med/9780190909291.003.0015
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 January 2021

The ReliantHeart aVAD© is a new intraventricular axial flow pump with pumping components that fit within the inflow cannula of the ventricular assist device (VAD). The aVAD© is an improvement over its predecessor, the extra-ventricular HeartAssist5 (HA5)™. The pumping components, inflow guide vane, impeller, and diffuser of the aVAD© are identical to those in the HA5, which in turn were derived from the original collaboration between Baylor College of Medicine and NASA. The current device provides excellent physiologic support for patients in end-stage heart failure and provides advanced ultrasonic flow measurements and performance data for wireless remote monitoring. In 2011 and 2012, the aVAD© was used successfully in calf studies as an artificial heart, with each ventricle being replaced by a modified HA5 VAD©. The two predecessor aVADs© were placed vertically, side by side, which provided a more compact total artificial heart with formable outflow graft protectors directed to the aorta and pulmonary artery. An ultrasonic flow probe accurately measures flow under all conditions, even in implants in place for years. The probe indicates flow in the range of –4 to +10 L/min with >95% accuracy. The probe can determine the relative contributions of the LVAD and native heart to adequate blood flow. The aVAD© meets the safety standards of the European Union and is sold in Europe. The aVAD is not yet available in the United States but is being tested under an FDA investigational device exemption.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.